Novartis Argentina company information, Employees & Contact Information

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Novartis

Novartis to Acquire Avidity Biosciences for US$12 Billion in Rare-Disease Push PharmiWeb.com

Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences Pharmaceutical Executive

Novartis to buy Avidity Biosciences in $12B deal to boost rare disease pipeline (NVS:NYSE) Seeking Alpha

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis Novartis

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront Novartis

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Novartis

Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company Novartis

New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline Novartis

Elizabeth McNally, M.D., Ph.D. Novartis

The 2025 Eurovision Song Contest Novartis

New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy Novartis

Addressing unmet needs for inherited neuromuscular diseases Novartis

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Novartis ranks first in 2024 Access to Medicine Index Novartis

Immunology disease research at Novartis Novartis

Managed access programs Novartis

Compassionate use: Providing access to much needed treatments Novartis

Therapeutic areas Novartis

About Novartis

Research and development Novartis

From black holes to AI driven drug discovery – collaboration wins the day Novartis

Human rights Novartis

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance Novartis

Sub-Saharan Africa Novartis

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2 Novartis

People and culture Novartis

Climate Novartis

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer Novartis

Coronavirus Novartis

Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline Novartis

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH Novartis

Early careers Novartis

Board of Directors Novartis

Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis

Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) Novartis

AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families Novartis

Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis Novartis

Negative impact of the IRA on patient access to innovative treatments Novartis

European Medicines Agency (EMA) approves safety label update for Novartis Beovu® Novartis

The data42 program shows Novartis’ intent to go big on data and digital Novartis

Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒² Novartis

Robots speed the pace of modern drug discovery Novartis

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa Novartis

Novartis data show rapid and effective disease activity control with remibrutinib (LOU064) in patients with chronic spontaneous urticaria Novartis

Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness Novartis

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML Novartis

Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer Novartis

Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials Novartis

Novartis receives EU approval for Leqvio®* (inclisiran), a first-in-class siRNA to lower cholesterol with two doses a year Novartis

Translational medicine research at Novartis Novartis

Novartis key multiple sclerosis product Gilenya® approved in China Novartis

Machine learning poised to accelerate drug discovery Novartis

Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease Novartis

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) Novartis

Novartis acquires Arctos Medical, expanding optogenetics portfolio to bring gene therapies to patients with severe vision loss Novartis

US FDA approves updated Novartis Beovu® label, to include additional safety information Novartis

Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 Novartis

Dividend information Novartis

Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA Novartis

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study Novartis

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance Novartis

Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility Novartis

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years Novartis

Novartis announces new CEO of Oncology Business Unit Novartis

Novartis provides an update on Phase III ligelizumab (QGE031) studies in chronic spontaneous urticaria (CSU) Novartis

Medical congresses and events Novartis

Novartis expands development programs for NASH through clinical collaboration with Allergan Novartis

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice Novartis

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia Novartis

Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response Novartis

Remembering men’s health this National Veterans and Military Families Month Novartis

Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer Novartis

Novartis appoints Elizabeth Barrett as Oncology Head Novartis

Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer Novartis

Novartis joins pharma-wide effort to meet global demand for COVID-19 vaccines Novartis

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia Novartis

New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) Novartis

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF) Novartis

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene Novartis

Novartis announces collaboration on HARMONIA, a Phase III, head-to-head trial evaluating Kisqali® vs. Ibrance®* in patients with HR+/HER2- advanced breast cancer Novartis

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients Novartis

Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma Novartis

Novartis resumes production and delivery of radioligand therapy medicines ahead of schedule Novartis

Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 Novartis

Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off Novartis

Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria Novartis

Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers Novartis

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran) Novartis

Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Novartis

Novartis access principles Novartis

Women in Science: Cathryn Clary Novartis

Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence Novartis

John D. Young Novartis

Shreeram Aradhye, M.D. Novartis

Novartis announces broad range of initiatives to respond to COVID-19 Pandemic; Creates USD 20 million global fund to support impacted communities Novartis

Novartis expands Africa Sickle Cell Disease program to Uganda and Tanzania Novartis

Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches Novartis

Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH Novartis